BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31612198)

  • 1. A systematic review and Meta-analysis on the association between Hand-Foot Syndrome (HFS) and Cancer Chemotherapy Efficacy.
    Falcone G; Arrigoni C; Dellafiore F; Gallucci F; Milani V; Boveri S; Ausili D; Caruso R
    Clin Ter; 2019; 170(5):e388-e395. PubMed ID: 31612198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
    Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
    Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology.
    Anderson RT; Keating KN; Doll HA; Camacho F
    Oncologist; 2015 Jul; 20(7):831-8. PubMed ID: 26084809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
    Pandy JGP; Franco PIG; Li RK
    Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
    Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
    Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.
    Chen M; Zhang L; Wang Q; Shen J
    PLoS One; 2013; 8(8):e72245. PubMed ID: 23977264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Urea Cream on Hand-Foot Syndrome in Patients Receiving Chemotherapy: A Meta-analysis.
    Lan TC; Tsou PH; Tam KW; Huang TW
    Cancer Nurs; 2022 Sep-Oct 01; 45(5):378-386. PubMed ID: 34483284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis.
    Jo SJ; Shin H; Jo S; Kwon O; Myung SK
    Clin Exp Dermatol; 2015 Apr; 40(3):260-70. PubMed ID: 25557587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
    Lian S; Zhang X; Zhang Y; Zhao Q
    Clin Exp Dermatol; 2021 Jun; 46(4):629-635. PubMed ID: 33190278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy.
    Hsu YH; Shen WC; Wang CH; Lin YF; Chen SC
    Eur J Oncol Nurs; 2019 Dec; 43():101670. PubMed ID: 31586645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.
    Shen X; Wang J; Yan X; Ren X; Wang F; Chen X; Xu Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1285-302. PubMed ID: 27154175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
    Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
    Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
    Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
    Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
    Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
    Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study.
    Komatsu H; Yagasaki K; Hirata K; Hamamoto Y
    Eur J Oncol Nurs; 2019 Feb; 38():65-69. PubMed ID: 30717938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
    Müller V; Fuxius S; Steffens CC; Lerchenmüller C; Luhn B; Vehling-Kaiser U; Hurst U; Hahn LJ; Soeling U; Wohlfarth T; Zaiss M
    Oncol Res Treat; 2014; 37(12):748-55. PubMed ID: 25531721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
    Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
    Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.